4YC6

CDK1/CKS1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.225 
  • R-Value Observed: 0.227 

wwPDB Validation   3D Report Full Report


This is version 2.0 of the entry. See complete history


Literature

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.

Brown, N.R.Korolchuk, S.Martin, M.P.Stanley, W.A.Moukhametzianov, R.Noble, M.E.Endicott, J.A.

(2015) Nat Commun 6: 6769-6769

  • DOI: 10.1038/ncomms7769
  • Primary Citation of Related Structures:  
    4Y72, 4YC3, 4YC6, 5HQ0

  • PubMed Abstract: 
  • CDK1 is the only essential cell cycle CDK in human cells and is required for successful completion of M-phase. It is the founding member of the CDK family and is conserved across all eukaryotes. Here we report the crystal structures of complexes of CDK1-Cks1 and CDK1-cyclin B-Cks2 ...

    CDK1 is the only essential cell cycle CDK in human cells and is required for successful completion of M-phase. It is the founding member of the CDK family and is conserved across all eukaryotes. Here we report the crystal structures of complexes of CDK1-Cks1 and CDK1-cyclin B-Cks2. These structures confirm the conserved nature of the inactive monomeric CDK fold and its ability to be remodelled by cyclin binding. Relative to CDK2-cyclin A, CDK1-cyclin B is less thermally stable, has a smaller interfacial surface, is more susceptible to activation segment dephosphorylation and shows differences in the substrate sequence features that determine activity. Both CDK1 and CDK2 are potential cancer targets for which selective compounds are required. We also describe the first structure of CDK1 bound to a potent ATP-competitive inhibitor and identify aspects of CDK1 structure and plasticity that might be exploited to develop CDK1-selective inhibitors.


    Organizational Affiliation

    Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle Upon Tyne, Tyne and Wear NE2 4HH, UK.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Cyclin-dependent kinase 1A, C, E, G297Homo sapiensMutation(s): 0 
Gene Names: CDK1CDC2CDC28ACDKN1P34CDC2
EC: 2.7.11.22 (PDB Primary Data), 2.7.11.23 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for P06493 (Homo sapiens)
Explore P06493 
Go to UniProtKB:  P06493
PHAROS:  P06493
GTEx:  ENSG00000170312 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP06493
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Cyclin-dependent kinases regulatory subunit 1B, D, F, H85Homo sapiensMutation(s): 0 
Gene Names: CKS1BCKS1PNAS-143PNAS-16
UniProt & NIH Common Fund Data Resources
Find proteins for P61024 (Homo sapiens)
Explore P61024 
Go to UniProtKB:  P61024
PHAROS:  P61024
GTEx:  ENSG00000173207 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP61024
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.225 
  • R-Value Observed: 0.227 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 66.817α = 90
b = 147.531β = 92.06
c = 87.297γ = 90
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
REFMACrefinement
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Medical Research Council (United Kingdom)United KingdomG0901526
Cancer Research UKUnited KingdomC240/A15751
Astex PharmaceuticalsUnited KingdomNICR-Alliance

Revision History  (Full details and data files)

  • Version 1.0: 2015-05-20
    Type: Initial release
  • Version 2.0: 2017-08-30
    Changes: Advisory, Atomic model, Author supporting evidence